In this issue:
Midostaurin + chemo for AML with a FLT3 mutation
Brentuximab vedotin in cutaneous T-cell lymphoma
HDC and autoSCT for primary CNS lymphoma
Radiotherapy in extranodal NK T-cell lymphoma
Azacitidine in MDS and CMML
Idarubicin vs daunorubicin induction for AML
CD33 splicing polymorphism and gemtuzumab ozogamicin
CD34+ haematopoietic stem and progenitor-derived NK cells in AML
Lenalidomide in R/R DLBCL
Pembrolizumab in R/R primary mediastinal LBCL
Please login below to download this issue (PDF)